Related Experiment Video
Updated: Jul 14, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[Growth inhibition of MG-63 cells by cyclin A2 gene-specific small interfering RNA]
Ye Liu1, Shun-Wu Fan, Jia-Yi Ding
1Department of Orthopaedics, Sir Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.
Objective:
To study the impact of small interference RNA (siRNA) targeting cyclin A2 gene on the growth of MG-63 and HSF cells and to explore whether cyclin A2 siRNAs could become a useful tool in the treatment of osteosarcoma.
Methods:
One pair of siRNA targeting the cyclin A2 mRNA and a pair of nonsense siRNA were designed according the current criteria. SiRNA was chemically synthesized and purified. The siRNA was transfected into osteosarcoma cell line MG-63 and normal human skin fibroblast (HSF) cells via oligofectamine. Cells transfected with nonsense siRNA served as the negative control and those only treated with PBS as the blank control group. Quantitative fluorescence RT-PCR, Western-blot, MTT assay, reverse transcriptase (RT)-PCR, flow cytometry and colony-forming test were employed to evaluate the efficacy of RNA interference. At the same time, the mRNA expression of PCNA and cyclin B1 in siRNA treated MG-63 cells were examined.
Results:
1 nmol/L, 10 nmol/L, 50 nmol/L and 100 nmol/L cyclin A2-siRNA can reduced cyclin A2 mRNA and protein expression respectively by 9.43%, 56.35%, 79.17% and 84.30% as compared with that of the blank control group, whereas the negative and blank control groups had similar expression levels. After 48 h treatment with 10 nmol/L siRNA, MG-63 cells were arrested in G0/G1 phase and the proliferation of this tumor cell was suppressed by 39.06% 48 h after transfection. Furthermore, the treated MG-63 cells showed less colony-forming ability. Increasing the siRNA concentration to 50 nmol/L can further inhibit the proliferation of MG-63 cells by 54.94%. In addition, the cyclin A2-depleted MG-63 cells showed decreased levels of PCNA and cyclin B1. In contrast, although cyclin A2 mRNA and protein expression in HSF reduced 58.13% 48 h after treatment by 50 nmol/L siRNA, these cells exhibited only a slight change in cell cycle, and no clear inhibition of proliferation and impaired plate colony-forming ability was observed.
Conclusion:
Cyclin A2 gene maybe served as a potential target for tumor therapy. RNA interference induces obvious inhibition of cyclin A2 mRNA and protein expression in MG-63 and HSF cells, which consequently downregulate the proliferation of MG-63 cells. There is few inhibitory effect on the proliferation by siRNAs for HSF cells. These results indicate that siRNAs against cyclin A2 could become a potential antiproliferative tool in future antitumor therapy.
Insights
Small interference RNA (siRNA) targeting cyclin A2 effectively inhibits osteosarcoma cell growth by reducing cyclin A2 expression. This targeted approach shows promise as a potential antiproliferative therapy for osteosarcoma with minimal impact on normal cells.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Background:
- Osteosarcoma is a primary bone malignancy with limited treatment options.
- Cyclin A2 is implicated in cell cycle progression and proliferation.
- Targeting specific genes offers a potential strategy for cancer therapy.
Purpose of the Study:
- To investigate the effect of small interference RNA (siRNA) targeting cyclin A2 on MG-63 osteosarcoma cells and human skin fibroblast (HSF) cells.
- To evaluate the potential of cyclin A2 siRNA as a therapeutic tool for osteosarcoma.
Main Methods:
- siRNA targeting cyclin A2 mRNA and a control siRNA were synthesized.
- Transfection of siRNA into MG-63 and HSF cells.
- Assessment of gene and protein expression (RT-PCR, Western-blot), cell proliferation (MTT assay, colony-forming test), and cell cycle (flow cytometry).
Main Results:
- Cyclin A2 siRNA significantly reduced cyclin A2 mRNA and protein expression in MG-63 cells in a dose-dependent manner.
- MG-63 cell proliferation was suppressed, with cell cycle arrest in the G0/G1 phase and reduced colony-forming ability.
- HSF cells showed reduced cyclin A2 expression but exhibited minimal impact on proliferation and cell cycle.
Conclusions:
- Cyclin A2 is a viable molecular target for osteosarcoma therapy.
- RNA interference targeting cyclin A2 effectively inhibits osteosarcoma cell proliferation.
- Cyclin A2 siRNA demonstrates potential as an antiproliferative agent for osteosarcoma treatment with a favorable safety profile for normal cells.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Experimental RNAi
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
Mitogens and the Cell Cycle
Negative Regulator Molecules
